Global Advisory Committee on Vaccine Safety, 9-10 June 2005.
D026683:Advisory Committees; D001500:BCG Vaccine / Q000009:adverse effects / Q000592:standards; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004352:Drug Resistance, Microbial; D017325:Hepatitis B Vaccines; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D022321:Japanese Encephalitis Vaccines / Q000009:adverse effects / Q000592:standards; D008458:Measles Vaccine / Q000009:adverse effects / Q000592:standards; D011054:Poliovirus Vaccine, Inactivated; D011358:Product Surveillance, Postmarketing; D012449:Safety; D013344:Subacute Sclerosing Panencephalitis / Q000139:chemically induced; D013849:Thimerosal / Q000493:pharmacokinetics; D014612:Vaccines / Q000009:adverse effects / Q000592:standards*; D017778:Vaccines, Combined / Q000009:adverse effects / Q000592:standards
D001500:BCG Vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; C426944:Hexavac; D022321:Japanese Encephalitis Vaccines; D008458:Measles Vaccine; D011054:Poliovirus Vaccine, Inactivated; D014612:Vaccines; D017778:Vaccines, Combined; D013849:Thimerosal; D007538:Isoniazid